Applying automated patch-clamp to disease modeling: recapitulate phenotypes of Brugada syndrome using iPSC-CMs

Recently, there have been great advances in cardiovascular channelopathy modeling and drug safety pharmacology using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The automated patch-clamp (APC) technique overcomes the disadvantages of manual patch-clamp (MPC) such as labor...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Wener, Li, Luo, Xiaojing, Ulbricht, Ying, Guan, Kaomei
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 07.06.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recently, there have been great advances in cardiovascular channelopathy modeling and drug safety pharmacology using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The automated patch-clamp (APC) technique overcomes the disadvantages of manual patch-clamp (MPC) such as labor intensive and low output. However, it was not clear whether the data generated by using the APC could be reliably used for iPSC-CM disease modeling. In this study, we improved the iPSC-CM preparation method by applying blebbistatin (BB, an excitation-contraction coupling uncoupler) in the whole APC procedures (dissociation, filtration, storage, and recording). Under non-BB buffered condition, iPSC-CMs in suspension showed a severe bleb-like morphology, however, BB-supplement leads to significant improvements in morphology and INa recording. We observe no effects of BB on action potential and field potential. Furthermore, APC faithfully recapitulates the single-cell electrophysiological phenotypes of iPSC-CMs derived from Brugada syndrome patients, as detected with MPC. Our study indicates that APC is capable of replacing MPC in the modeling of cardiac channelopathies using human iPSC-CMs by providing high quality data with higher throughput. Competing Interest Statement The authors have declared no competing interest.
DOI:10.1101/2021.06.07.447362